Clinical Guidelines
Feature

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia

  • By

  • July 22, 2019

  • 13 min

Share

Acute myeloid leukemia (AML) is a hematologic cancer characterized by the uncontrolled growth of immature blood cells. Prognosis depends on patient factors like age and genetic markers. While younger patients may achieve remission with standard therapies like daunorubicin and cytarabine, older patients often struggle. Treatment options include hematopoietic stem cell transplant for eligible patients and new targeted therapies such as ivosidenib, an IDH1 inhibitor. This agent shows promise for relapsed/refractory AML cases, with clinical trials ongoing to evaluate its efficacy and safety.

Original Source(s)

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia

  • July 22, 2019

  • 13 min

Related Content

Smarter Digital Morphology Triage

A diffusion-based approach aims to handle domain shifts, slide variability, and rare cell appearances

  • January 30, 2026

  • 3 min
When Halting Myelofibrosis Progression Fails, Try Changing Its Course Instead

The decades-long research efforts of a consortium, led by Mount Sinai researchers, to deplete myelofibrosis stem cells altogether—instead of merely stopping proliferation—has received renewed funding.

  • by

  • January 11, 2024

  • 1 min
Towards Rapid Microbial Testing Methods

We need more rapid sterility testing methods for frozen CAR-T drug products; here’s one potential approach